Zenas BioPharma, Inc. Common Stock (ZBIO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Zenas BioPharma, Inc. Common Stock (ZBIO) has a cash flow conversion efficiency ratio of -0.224x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-75.20 Million) by net assets ($335.83 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ZBIO equity to assets ratio to measure how much of total assets are equity-financed.
Zenas BioPharma, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Zenas BioPharma, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Zenas BioPharma, Inc. Common Stock to evaluate the quality of earnings relative to operating cash generation.
Zenas BioPharma, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zenas BioPharma, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tibet Mineral Development Co Ltd
SHE:000762
|
0.009x |
|
Pharvaris BV
NASDAQ:PHVS
|
-0.098x |
|
Guangdong Advertising Co Ltd
SHE:002400
|
0.025x |
|
Ta Liang Technology Co Ltd
TW:3167
|
0.117x |
|
Mercuries Life Insurance Co Ltd
TW:2867
|
-0.072x |
|
Tibet GaoZheng Explosive Co Ltd
SHE:002827
|
0.036x |
|
BitVentures Limited
NASDAQ:BVC
|
N/A |
|
Isrotel -L
TA:ISRO
|
0.097x |
Annual Cash Flow Conversion Efficiency for Zenas BioPharma, Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of Zenas BioPharma, Inc. Common Stock from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see ZBIO stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $242.14 Million | $-172.33 Million | -0.712x | -85.82% |
| 2024-12-31 | $312.46 Million | $-119.67 Million | -0.383x | -383.18% |
| 2023-12-31 | $-225.72 Million | $-30.53 Million | 0.135x | -60.39% |
| 2022-12-31 | $-192.29 Million | $-65.65 Million | 0.341x | -- |
About Zenas BioPharma, Inc. Common Stock
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc"RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, an… Read more